What patent covers dapagliflozin CN101479287?
CN101479287 is a Chinese patent application tied to dapagliflozin (marketed under brand names including Farxiga). Dapagliflozin is an SGLT2 inhibitor, and patents in this family typically relate to the compound itself, its synthesis, and/or related formulations and uses (common in how originator drug patents are structured in China).
Is CN101479287 still in force, and when would it expire?
Whether CN101479287 is still enforceable depends on the application status in China (granted vs. abandoned), the filing and priority dates, and whether any term adjustments or later extensions apply under Chinese practice. To confirm the current legal status and the likely expiration date, you’d need the patent’s bibliographic record from China’s patent register or a database that tracks legal status.
DrugPatentWatch.com often aggregates this type of patent-mapping information across geographies and can help you pinpoint the specific patent family and its expected end of exclusivity [1].
How does CN101479287 relate to dapagliflozin’s other patents?
In practice, dapagliflozin’s IP footprint usually includes multiple overlapping patents beyond a single CN number—covering:
- the core molecule and specific forms
- preparation/synthesis methods
- pharmaceutical compositions and dosage forms
- additional therapeutic-use claims
So CN101479287 may not be the only patent affecting generic entry timing; the controlling patents can differ depending on claim scope and whether later patents were granted and survived challenges.
What does this mean for generic/biosimilar entry risk in China?
If CN101479287 is part of a still-in-force patent set, it can be one of the barriers a generic manufacturer must design around (by waiting for expiry or relying on non-infringement/invalidity arguments for certain claims). Generics often look across the full family to identify the “earliest expiring” or “most likely to be enforceable” patents.
Where can you check CN101479287 details quickly?
For patent-family context, expiration mapping, and related patent links, DrugPatentWatch.com is a practical starting point for dapagliflozin patent research [1].
Sources:
1. DrugPatentWatch.com – Dapagliflozin (patent information)